Cite
Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
MLA
Oliveras-Ferraros, Cristina, et al. “Epithelial-to-Mesenchymal Transition (EMT) Confers Primary Resistance to Trastuzumab (Herceptin).” Cell Cycle, vol. 11, no. 21, Nov. 2012, pp. 4020–32. EBSCOhost, https://doi.org/10.4161/cc.22225.
APA
Oliveras-Ferraros, C., Corominas-Faja, B., Cufí, S., Vazquez-Martin, A., Martin-Castillo, B., Iglesias, J. M., López-Bonet, E., Martin, Á. G., & Menendez, J. A. (2012). Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle, 11(21), 4020–4032. https://doi.org/10.4161/cc.22225
Chicago
Oliveras-Ferraros, Cristina, Bruna Corominas-Faja, Sílvia Cufí, Alejandro Vazquez-Martin, Begoña Martin-Castillo, Juan Manuel Iglesias, Eugeni López-Bonet, Ángel G. Martin, and Javier A. Menendez. 2012. “Epithelial-to-Mesenchymal Transition (EMT) Confers Primary Resistance to Trastuzumab (Herceptin).” Cell Cycle 11 (21): 4020–32. doi:10.4161/cc.22225.